Overview

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

Status:
NOT_YET_RECRUITING

Trial end date:
2031-06-01

Target enrollment:

Participant gender:

Summary

The goal of this study is to determine whether the addition of Androgen Deprivation Therapy (ADT) utilizing the study drug ELIGARD to Recurrence- Directed Therapy (RDT) improves progression-free survival (PFS) compared to RDT alone in patients with early radio-recurrent oligo-metastatic castrate / hormone sensitive prostate cancer (romCSPC). Participants will be assessed at standard of care clinic visits every 3 months. The follow-up period is 36 months.

Phase:

PHASE2

Details

Lead Sponsor:

Ontario Clinical Oncology Group (OCOG)

Collaborators:

Ontario Clinical Oncology Group (OCOG) - McMaster University
TOLMAR PHARMACEUTIQUES CANADA, INC.

Treatments:

luprolide acetate gel depot